Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Thrombosis Journal
Published in: Thrombosis Journal 1/2013

Open Access 01-12-2013 | Case report

Resolution of left atrial appendage thrombus with apixaban

Authors: Tohru Kawakami, Hiroko Kobayakawa, Hiroyoshi Ohno, Nobukiyo Tanaka, Hiroki Ishihara

Published in: Thrombosis Journal | Issue 1/2013

Login to get access

Abstract

Left atrial appendage (LAA) thrombosis is an important cause of cardiogenic cerebral thromboembolism. Apixaban is a member of the class of novel oral anticoagulants (NOAC) and is superior to warfarin in preventing stroke or systemic embolism, causes less bleeding, and results in lower mortality in patients with atrial fibrillation. There are few reports of resolution of LAA thrombus with other NOAC. We present a 72-year-old male patient with persistent atrial fibrillation associated with left atrial thrombus. Sixteen days of apixaban treatment showed complete thrombus resolution. In this study, soluble fibrin and D-dimer levels decreased without prolongation of international normalized ratio (INR) and activated partial thromboplastin time (APTT).
Appendix
Available only for authorised users
Literature
1.
The European Atrial Fibrillation Trial Study Group: Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med 1995, 333: 5-10.CrossRef
2.
Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, et al.: Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365: 981-992. 10.1056/NEJMoa1107039CrossRefPubMed
3.
Vidal A, Vanerio G: Dabigatran and left atrial appendage thrombus. J Thromb Thrombolysis 2012, 34: 545-547. 10.1007/s11239-012-0747-1CrossRefPubMed
4.
Hammerstingl C, Potzsch B, Nickenig G: Resolution of giant left atrial appendage thrombus with rivaroxaban. Thromb Haemost 2013, 109: 583-584. 10.1160/TH12-11-0821CrossRefPubMed
5.
Kimura M, Wasaki Y, Ogawa H, Nakatsuka M, Wakeyama T, Iwami T, Ono K, Nakao F, Matsuzaki M: Effect of low-intensity warfarin therapy on left atrial thrombus resolution in patients with nonvalvular atrial fibrillation: a transesophageal echocardiographic study. Jpn Circ J 2001, 65: 271-274. 10.1253/jcj.65.271CrossRefPubMed
6.
Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Guyton RA, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Wann LS, Curtis AB, Ellenbogen KA, Estes NA 3rd, Ezekowitz MD, Jackman WM, January CT, Lowe JE, Page RL, Slotwiner DJ, Stevenson WG, Tracy CM, Fuster V, Ryden LE, Cannom DS, Crijns HJ, et al.: Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American college of cardiology/American heart association task force on practice guidelines. J Am Coll Cardiol 2006, 2013(61):1935-1944.
7.
Nair CK, Holmberg MJ, Aronow WS, Shen X, Li H, Lakkireddy D: Thromboembolism in patients with atrial fibrillation with and without left atrial thrombus documented by transesophageal echocardiography. Am J Ther 2009, 16: 385-392. 10.1097/MJT.0b013e3181727b42CrossRefPubMed
8.
Habara S, Dote K, Kato M, Sasaki S, Goto K, Takemoto H, Hasegawa D, Matsuda O: Prediction of left atrial appendage thrombi in non-valvular atrial fibrillation. Eur Heart J 2007, 28: 2217-2222. 10.1093/eurheartj/ehm356CrossRefPubMed
9.
Mitusch R, Siemens HJ, Garbe M, Wagner T, Sheikhzadeh A, Diederich KW: Detection of a hypercoagulable state in nonvalvular atrial fibrillation and the effect of anticoagulant therapy. Thromb Haemost 1996, 75: 219-223.PubMed
10.
Ota S, Wada H, Nobori T, Kobayashi T, Nishio M, Nishioka Y, Noda M, Sakaguchi A, Abe Y, Nishioka J, Ishikura K, Yamada N, Nakano T: Diagnosis of deep vein thrombosis by plasma-soluble fibrin or D-dimer. Am J Hematol 2005, 79: 274-280. 10.1002/ajh.20396CrossRefPubMed
11.
Palareti G, Cosmi B, Legnani C, Tosetto A, Brusi C, Iorio A, Pengo V, Ghirarduzzi A, Pattacini C, Testa S, Lensing AW, Tripodi A: D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 2006, 355: 1780-1789. 10.1056/NEJMoa054444CrossRefPubMed
12.
Ruiz-Gimenez N, Friera A, Artieda P, Caballero P, Sanchez Molini P, Morales M, Suarez C: Rapid D-dimer test combined a clinical model for deep vein thrombosis. Validation with ultrasonography and clinical follow-up in 383 patients. Thromb Haemost 2004, 91: 1237-1246.PubMed
13.
Wada H, Kobayashi T, Abe Y, Hatada T, Yamada N, Sudo A, Uchida A, Nobori T: Elevated levels of soluble fibrin or D-dimer indicate high risk of thrombosis. J Thromb Haemost 2006, 4: 1253-1258. 10.1111/j.1538-7836.2006.01942.xCrossRefPubMed
14.
Wells PS, Anderson DR, Rodger M, Forgie M, Kearon C, Dreyer J, Kovacs G, Mitchell M, Lewandowski B, Kovacs MJ: Evaluation of D-dimer in the diagnosis of suspected deep-vein thrombosis. N Engl J Med 2003, 349: 1227-1235. 10.1056/NEJMoa023153CrossRefPubMed
15.
Klein AL, Grimm RA, Murray RD, Apperson-Hansen C, Asinger RW, Black IW, Davidoff R, Erbel R, Halperin JL, Orsinelli DA, Porter TR, Stoddard MF: Use of transesophageal echocardiography to guide cardioversion in patients with atrial fibrillation. N Engl J Med 2001, 344: 1411-1420. 10.1056/NEJM200105103441901CrossRefPubMed
16.
Klein AL, Murray RD, Grimm RA: Role of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation. J Am Coll Cardiol 2001, 37: 691-704. 10.1016/S0735-1097(00)01178-5CrossRefPubMed
17.
Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iwamoto K, Tajiri M: Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation - the J-ROCKET AF study. Circ J 2012, 76: 2104-2111. 10.1253/circj.CJ-12-0454CrossRefPubMed
Metadata
Title
Resolution of left atrial appendage thrombus with apixaban
Authors
Tohru Kawakami
Hiroko Kobayakawa
Hiroyoshi Ohno
Nobukiyo Tanaka
Hiroki Ishihara
Publication date
01-12-2013
Publisher
BioMed Central
Published in
Thrombosis Journal / Issue 1/2013
Electronic ISSN: 1477-9560
DOI
https://doi.org/10.1186/1477-9560-11-26

Other articles of this Issue 1/2013

Thrombosis Journal 1/2013 Go to the issue

Original clinical investigation

Activated protein C resistance in Behcet’s disease

Original clinical investigation

Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies

Case report

Protein-C deficiency presenting as pulmonary embolism and myocardial infarction in the same patient

Original basic research

Dabigatran versus warfarin under standard or pharmacogenetic-guided management for the prevention of stroke and systemic thromboembolism in patients with atrial fibrillation: a cost/utility analysis using an analytic decision model

Review

The new oral anti-coagulants and the phase 3 clinical trials - a systematic review of the literature

Review

Emphasis on the Role of PF4 in the Incidence, Pathophysiology and Treatment of Heparin Induced Thrombocytopenia
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits